Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee Schwartzberg

Showing results (51-60 of 112) with videos related to

Pageof 12
Sort By:
Drug Design, Development and Therapy|September 19, 2017
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populationsBernardo Leon Rapoport, Matti Aapro, Martin R Chasen, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 26, 2016
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapyMartin Chasen, Laszlo Urban, Ian Schnadig, et al.
Cancer|November 3, 2011
Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancerAman Buzdar, Charles Vogel, Lee Schwartzberg, et al.
Clinical Breast Cancer|March 30, 2021
Advances in Therapeutic Approaches for Triple-Negative Breast CancerReshma Mahtani, Muaiad Kittaneh, Kevin Kalinsky, et al.
Breast Cancer Research and Treatment|April 5, 2014
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancerKristi McIntyre, Joyce O'Shaughnessy, Lee Schwartzberg, et al.
Frontiers in Oncology|February 25, 2022
Social Disparities of Pain and Pain Intensity Among Women Diagnosed With Early Stage Breast CancerHyo Young Choi, Ilana Graetz, Arash Shaban-Nejad, et al.
Cancer Medicine|April 11, 2019
Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studiesLee Schwartzberg, Meinolf Karthaus, Giorgia Rossi, et al.
Journal of the National Cancer Institute|December 8, 2025
Potential role of perceived discrimination and sociodemographics on racial disparities in breast cancer symptom burdenXin Hu, Clara Cai, Sara Arshad, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 20, 2023
2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agentsFlorian Scotté, Lee Schwartzberg, Hirotoshi Iihara, et al.
Cancer Treatment Reviews|July 30, 2015
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancerJ Randolph Hecht, Jean-Yves Douillard, Lee Schwartzberg, et al.
Pageof 12

Showing results (51-60 of 112) with videos related to

Sort By:
Pageof 12
Drug Design, Development and Therapy|September 19, 2017
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populationsBernardo Leon Rapoport, Matti Aapro, Martin R Chasen, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 26, 2016
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapyMartin Chasen, Laszlo Urban, Ian Schnadig, et al.
Cancer|November 3, 2011
Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancerAman Buzdar, Charles Vogel, Lee Schwartzberg, et al.
Clinical Breast Cancer|March 30, 2021
Advances in Therapeutic Approaches for Triple-Negative Breast CancerReshma Mahtani, Muaiad Kittaneh, Kevin Kalinsky, et al.
Breast Cancer Research and Treatment|April 5, 2014
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancerKristi McIntyre, Joyce O'Shaughnessy, Lee Schwartzberg, et al.
Frontiers in Oncology|February 25, 2022
Social Disparities of Pain and Pain Intensity Among Women Diagnosed With Early Stage Breast CancerHyo Young Choi, Ilana Graetz, Arash Shaban-Nejad, et al.
Cancer Medicine|April 11, 2019
Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studiesLee Schwartzberg, Meinolf Karthaus, Giorgia Rossi, et al.
Journal of the National Cancer Institute|December 8, 2025
Potential role of perceived discrimination and sociodemographics on racial disparities in breast cancer symptom burdenXin Hu, Clara Cai, Sara Arshad, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 20, 2023
2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agentsFlorian Scotté, Lee Schwartzberg, Hirotoshi Iihara, et al.
Cancer Treatment Reviews|July 30, 2015
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancerJ Randolph Hecht, Jean-Yves Douillard, Lee Schwartzberg, et al.
Pageof 12